Today: 20 March 2026
Subscribe
Browse Category

Pharmaceuticals 4 November 2025 - 11 November 2025

Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]

Quoin Pharmaceuticals (QNRX) Soars After Hitting 4%/5% Topical Rapamycin Targets; Clinical Batches This Quarter, Human Trials 1H 2026 [Nov. 11, 2025]

Quoin Pharmaceuticals announced it achieved 4% rapamycin in a topical lotion and 5% in a dermal patch, clearing a key formulation barrier for human trials. QNRX shares surged, with pre-market gains near 66%. Clinical and stability batch manufacturing is set for late 2025, with first-in-human studies planned for early 2026 targeting microcystic lymphatic and venous malformations.
11 November 2025
···
enGene (ENGN) soars after detailing 62% 6‑month complete response in pivotal bladder‑cancer trial; BLA still targeted for 2H 2026

enGene (ENGN) soars after detailing 62% 6‑month complete response in pivotal bladder‑cancer trial; BLA still targeted for 2H 2026

enGene Holdings reported a 62% complete response rate at 6 months in its pivotal Phase 2 LEGEND trial of detalimogene voraplasmid for high-risk, BCG-unresponsive NMIBC with CIS. The company enrolled 125 patients, above target. Shares surged as much as 62% pre-market after the update. Safety data showed 42% of patients had treatment-related adverse events, mostly mild.
11 November 2025
···
Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly agreed to pay $75 million upfront and over $400 million in milestones for global rights to MeiraGTx’s pediatric blindness gene therapy. The company also announced an AI drug discovery partnership with Insilico Medicine, worth over $100 million in potential payments. Leerink Partners upgraded Lilly shares and raised its price target to $1,104, sending the stock up about 5% intraday.
10 November 2025
······
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10 Billion Metsera Deal as Novo Nordisk Exits—What It Means for the Obesity Drug Race (Nov. 8, 2025)

Pfizer secured a deal to acquire obesity-drug developer Metsera for up to $10 billion after Novo Nordisk withdrew its rival bid, citing FTC antitrust concerns. Metsera shareholders are set to vote Nov. 13 on Pfizer’s offer of $65.60 in cash plus up to $20.65 per share in contingent value rights. Metsera’s board recommended approval. Metsera shares surged nearly 60% during the bidding.
8 November 2025
···
Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer (PFE) Clinches $10B Metsera Deal, Beating Novo Nordisk — What the Winning Bid Means for the Obesity-Drug Race (Nov. 8, 2025)

Pfizer will acquire Metsera for up to $10 billion after Metsera accepted a revised cash-and-CVR offer late Friday, ending Novo Nordisk’s competing bid. Metsera’s board cited U.S. antitrust risks with Novo’s proposal following FTC feedback. Pfizer will pay $65.60 per share plus a contingent value right of up to $20.65. A shareholder vote is set for Nov. 13, with closing expected soon after.
8 November 2025
···
Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Metsera (NASDAQ: MTSR): Pfizer Clinches $10B Deal as Novo Nordisk Bows Out — What to Know Today (Nov. 8, 2025)

Pfizer agreed to acquire Metsera for up to $10 billion, outbidding Novo Nordisk and ending a heated takeover battle. Metsera shareholders will vote on the deal Nov. 13, with closing expected soon after pending approvals. Shares of MTSR surged to $83.18 following the announcement. Regulators are expected to review the deal’s impact on the obesity-drug market.
8 November 2025
·····
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk Stock Today (Nov 7, 2025): NVO Slips as U.S. Wegovy/Ozempic Price Cuts Take Center Stage; Medicare Coverage, FTC Scrutiny and Metsera Bid in Focus

Novo Nordisk shares fell about 2–4% Friday after the company and Eli Lilly agreed to cut U.S. prices for GLP‑1 drugs, including Medicare coverage, reducing monthly costs to $149–$350. Novo expects a low single-digit hit to global sales growth in 2026. A Delaware court backed Novo’s bid for Metsera, while U.S. regulators flagged antitrust concerns. Novo missed Q3 estimates and lowered its full-year outlook.
7 November 2025
··
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

NVO Stock Today (Nov 6, 2025): Novo Nordisk volatile as White House pricing deal reshapes GLP‑1 market—what it means for Wegovy, Ozempic and investors

Novo Nordisk shares fell about 2.4% after the White House announced a deal with Novo and Eli Lilly to expand Medicare coverage and lower prices for anti-obesity drugs. The agreement includes a Medicare Part D pilot starting in 2026, lower prices in Medicare, Medicaid, and cash channels, and a three-year tariff exemption. Novo expects a low single-digit hit to 2026 global sales growth. NVO traded at $47.30 as of 12:51 p.m. ET.
6 November 2025
··
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Pops as White House Strikes Obesity-Drug Pricing Deal; New 20% Weight‑Loss Data Fuels Momentum — Today, November 6, 2025

Eli Lilly shares rose midday, trading near $935.89, after the White House announced expanded Medicare coverage and lower prices for obesity drugs, including Zepbound. New Phase 2 data showed Lilly’s eloralintide led to up to 20.1% weight loss, with Phase 3 trials set for December 2025. BMO Capital raised its price target to $1,100.
6 November 2025
·
Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax raised its FY2025 adjusted revenue outlook to $1.04–$1.06 billion after reporting Q3 revenue of $70 million, above estimates. The company posted a GAAP net loss of $202 million for the quarter, impacted by $126 million in non-cash charges tied to Maryland site consolidation and debt. Two $25 million milestone payments from Sanofi will be recognized in Q4. Cash stood at $778 million as of September 30.
6 November 2025
·····
Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna reported Q3 2025 revenue of $1.02 billion and a GAAP loss of $0.51 per share, both ahead of analyst forecasts, driven by $971 million in COVID-19 vaccine sales. The company narrowed its full-year revenue outlook to $1.6–$2.0 billion, cut operating-expense guidance by $700 million, and raised its year-end cash target. Shares rose pre-market but traded unevenly during the session.
6 November 2025
··
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) today: Court denies bid to block Novo–Metsera deal; Pfizer preps sweeter offer and leans on higher 2025 EPS outlook

A Delaware court denied Pfizer’s request to block Metsera from ending their merger deal in favor of Novo Nordisk’s higher bid. Pfizer plans to raise its offer after Novo’s proposal reached up to $10 billion. FTC staff warned Novo’s bid structure could violate pre-merger rules. Pfizer shares traded near $24.61 midday Thursday.
6 November 2025
····
Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer closed at $24.45 on Nov. 5, 2025, with a market cap near $138 billion, more than 60% below its pandemic-era peak. Q3 revenue fell 6% to about $16.7 billion, while adjusted earnings beat forecasts at $0.87 per share. COVID-19 product sales continued to drop sharply. Pfizer is in a bidding war with Novo Nordisk for obesity drug developer Metsera.
5 November 2025
··
Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

Biohaven (BHVN) Stock Plunges on FDA Setback – Will Its Biotech Pipeline Fuel a Comeback?

Biohaven Ltd. shares plunged about 40% on Nov. 5, 2025, after the FDA rejected its lead drug VYGLXIA for spinocerebellar ataxia, citing trial design and data issues. The company will cut R&D spending by 60% and halt non-priority programs. Analysts downgraded the stock, which now trades near $8–9, down over 70% year-over-year. Biohaven reported a $198 million net loss in Q2 with $408 million in cash.
5 November 2025
·
Teva Stock Soars on Earnings Beat: Inside Teva’s 2025 Comeback and What’s Next for Investors

Teva Stock Soars on Earnings Beat: Inside Teva’s 2025 Comeback and What’s Next for Investors

Teva Pharmaceutical reported Q3 2025 adjusted EPS of $0.78 on $4.48 billion revenue, beating estimates and sending shares up 10–11% to a new 52-week high. The company raised 2025 guidance, citing strong sales of Austedo and other branded drugs, and Fitch upgraded its credit rating in May. Debt fell to $16.79 billion. Teva’s forward P/E remains below industry averages despite the stock’s sharp recovery.
5 November 2025
···
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk’s Weight-Loss Drug Boom Hits a Wall – Wegovy Slowdown Sparks Stock Slump and Forecast Cut

Novo Nordisk cut its 2025 sales and profit outlook for the fourth time this year after third-quarter results missed forecasts, with Wegovy revenues below expectations. Operating profit fell 30% due to restructuring costs. The company faces rising competition from Eli Lilly and U.S. copycat drugs, as well as mounting pricing pressure. Shares have dropped up to 50% in 2025; Novo plans 9,000 job cuts and a $10 billion bid for Metsera.
5 November 2025
···
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk raised its offer for Metsera to about $10 billion, topping Pfizer’s $8.1 billion bid. Metsera’s board labeled Novo’s bid “superior,” triggering a two-day window for Pfizer to respond. Pfizer has filed lawsuits in Delaware and federal court to block Novo’s challenge. Shares in Metsera jumped 20% after the news, while Novo’s stock slipped.
4 November 2025
···
Fentanyl ‘Nuke’ & Anti-Woke Crusade: Palantir CEO’s Wild Earnings Call Fuels $490 B AI Surge

Fentanyl ‘Nuke’ & Anti-Woke Crusade: Palantir CEO’s Wild Earnings Call Fuels $490 B AI Surge

Palantir Technologies reported Q3 2025 revenue of nearly $1.2 billion, up 63% year-on-year, and raised full-year guidance to $4.4 billion. CEO Alex Karp declared Palantir “the first company to be completely anti-woke,” defended its work with ICE and Israel, and told critics to “get some popcorn.” Shares surged 200% in 2025 but fell 7% after earnings on valuation concerns.
4 November 2025
··
Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer reported Q3 2025 adjusted earnings of $0.87 per share, beating estimates, with revenue at $16.65–$16.7 billion. The company raised its full-year profit outlook to $3.00–$3.15 EPS. Sales of COVID products plunged, but demand for Eliquis and Vyndaqel rose. Pfizer sued Novo Nordisk over a $7.3 billion bid for obesity drugmaker Metsera; a court hearing is set for Nov. 4.
4 November 2025
···
1 … 32 33 34 35 36 … 38

Stock Market Today

  • US Stocks Fall Amid Middle East Crisis and Rising Yields; Dow Drops 239 Points
    March 20, 2026, 3:48 PM EDT. U.S. stocks dropped sharply on March 20, 2026, driven by escalating Middle East conflict and a surge in Treasury yields. The Dow Jones fell 239 points (-0.52%) to 45,751. The S&P 500 slid 0.84% and the Nasdaq declined 1.28%, pressured by tech sell-offs including a 26% crash in Super Micro Computer after federal charges. Energy stocks showed resilience as crude oil prices neared $97.50 a barrel, stoking inflation fears. The 10-year Treasury yield jumped to 4.38%, raising rate hike odds. Gold and silver made tentative gains, while Bitcoin steadied near $70,000. Investors are poised for volatility pending geopolitical developments and economic data, with higher oil prices and inflation concerns clouding the outlook.
Go toTop